CompoundedRxClaimsAudit: what your telehealth or med-spa page says about compounded drugs

Enter a telehealth, weight-loss, hormone or med-spa page. We read the served page and report what we observe: whether compounded drugs are marketed and paired with a "not FDA-approved" statement, wording that presents them as generic, identical or FDA-approved, brand-name drug trademarks on the page, prescription and eligibility wording, risk and side-effect information, a LegitScript seal, and medical-supervision and state-licensure statements. Each observation cites the source it relates to.

Automated observations of the publicly served HTML of one page (text, links and scripts; content in images, videos or added later by JavaScript may not be seen). Context: FD&C Act sections 503A and 503B (21 U.S.C. 353a, 353b: conditions for compounded drugs), section 502(bb) (21 U.S.C. 352(bb): a compounded drug is misbranded if its advertising or promotion is false or misleading), and FDA's statements that compounded drugs are not FDA-approved; state medical and pharmacy boards set supervision and licensure rules. Not legal advice and not a compliance certification.